Pharmaceutical

CTX-310 by CRISPR Therapeutics for Heterozygous familia...

Jul 6, 2024

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Ph...

CTX-310 by CRISPR Therapeutics for Homozygous Familial ...

Jul 6, 2024

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Ph...

CTX-310 by CRISPR Therapeutics for Hypertriglyceridemia...

Jul 6, 2024

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Ph...

BNT-325 by Duality Biologics (Shanghai) for Metastatic ...

Jul 6, 2024

BNT-325 is under clinical development by Duality Biologics (Shanghai) and curren...

CAN-3110 by Candel Therapeutics for High-Grade Glioma: ...

Jul 6, 2024

CAN-3110 is under clinical development by Candel Therapeutics and currently in P...

ICTCAR-028 by Innovative Cellular Therapeutics for Hema...

Jul 6, 2024

ICTCAR-028 is under clinical development by Innovative Cellular Therapeutics and...

LP-184 by Starlight Therapeutics for Non-Small Cell Lun...

Jul 6, 2024

LP-184 is under clinical development by Starlight Therapeutics and currently in ...

Johnson & Johnson gains FDA and EC approvals for TB treatment

Johnson & Johnson gains FDA and EC approvals for TB tre...

Jul 4, 2024

Johnson & Johnson (J&J) has received the US FDA and EC approvals for SIRTURO (be...

Moderna’s mRNA influenza vaccine receives $176m boost

Moderna’s mRNA influenza vaccine receives $176m boost

Jul 4, 2024

Moderna has received a grant of $176m through the RRPV Consortium to expedite th...

Left in limbo: When pharma halts rare disease research

Left in limbo: When pharma halts rare disease research

Jul 4, 2024

Academic institutions and nonprofit organisations are jumping in to save access ...

Eli Lilly’s donanemab wins FDA approval for Alzheimer’s disease

Eli Lilly’s donanemab wins FDA approval for Alzheimer’s...

Jul 4, 2024

Leqembi will now face a challenger as donanemab enters the market under the bran...

Beacon secures $170m to advance ophthalmic gene therapies

Beacon secures $170m to advance ophthalmic gene therapies

Jul 4, 2024

Beacon’s lead candidate AGTC-501 is currently in a Phase II/III clinical trial f...

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

Biogen completes $1.15bn HI-Bio acquisition to expand i...

Jul 4, 2024

The takeover, which includes the candidate felzartamab, for immune-mediated dise...

Emergent scores US medical countermeasure contracts worth over $250m

Emergent scores US medical countermeasure contracts wor...

Jul 4, 2024

Emergent will supply vaccines for anthrax and smallpox, VIV for treating smallpo...

EMA approves Sanofi’s Dupixent for COPD treatment in adults

EMA approves Sanofi’s Dupixent for COPD treatment in ad...

Jul 4, 2024

The EMA has granted approval to Sanofi's Dupixent for adults with uncontrolled c...

GSK and CureVac restructure mRNA vaccine development deal

GSK and CureVac restructure mRNA vaccine development deal

Jul 4, 2024

GSK and CureVac have announced the restructuring of their existing partnership i...

48
49
50
51
52